Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Transient Ischemic Attack l: Introduction01:26

Transient Ischemic Attack l: Introduction

A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by a temporary, focal reduction in cerebral blood flow. Although symptoms resemble those of an ischemic stroke, the interruption in perfusion is short-lived and does not cause permanent infarction. TIAs are clinically important because they often serve as early warning events for future stroke.Mechanisms of Transient Cerebral IschemiaTransient cerebral ischemia may arise through several mechanisms. One...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single center retrospective comparison of bivalirudin and unfractionated heparin for therapeutic anticoagulation in pediatric patients.

Thrombosis research·2026
Same author

Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study.

Haemophilia : the official journal of the World Federation of Hemophilia·2025
Same author

Building access to care for Women and Girls<sup>+</sup> with Bleeding Disorders: the WGBD Clinic of Excellence Model.

Research and practice in thrombosis and haemostasis·2025
Same author

Inhibitor development and clinical characteristics in children with severe hemophilia A in the ATHN 8 US cohort study.

Blood vessels, thrombosis & hemostasis·2025
Same author

Testing for bleeding disorders in child abuse: AAP recommendation adherence and testing results.

Child abuse & neglect·2025
Same author

Long-term follow-up of patients with congenital thrombotic thrombocytopenia purpura receiving a plasma-derived factor VIII (Koate) that contains ADAMTS13.

Haemophilia : the official journal of the World Federation of Hemophilia·2023
Same journal

Phagocytized neutrophil fragments in the bone marrow: a phenomenon most commonly associated with hodgkin lymphoma.

ISRN hematology·2014
Same journal

Preventative effects of caffeic Acid phenyl ester on cadmium intoxication induced hematological and blood coagulation disturbances and hepatorenal damage in rats.

ISRN hematology·2014
Same journal

Clinicohematological study of thrombocytosis in children.

ISRN hematology·2014
Same journal

Coexisting iron deficiency anemia and Beta thalassemia trait: effect of iron therapy on red cell parameters and hemoglobin subtypes.

ISRN hematology·2014
Same journal

Relevant aspects of centrifugation step in the preparation of platelet-rich plasma.

ISRN hematology·2014
Same journal

Prevalence of deletional alpha thalassemia and sickle gene in a tribal dominated malaria endemic area of eastern India.

ISRN hematology·2014
See all related articles

Related Experiment Video

Updated: May 19, 2026

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
11:08

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

Thrombotic microangiopathies.

Mohamed Radhi1, Shannon L Carpenter

  • 1Pediatric Hematology/Oncology/Stem Cell Transplant, Children's Mercy Hospital, Kansas City, MO 64108, USA.

ISRN Hematology
|August 14, 2012
PubMed
Summary
This summary is machine-generated.

Thrombotic microangiopathy involves microvascular blood clots causing red blood cell damage and low platelets. This review explores diverse causes, including TTP/HUS, infections, and medications.

More Related Videos

Microvascular Embolism Mouse Model for In Vivo Two-photon Microscopy Using Fluorescent Polystyrene Microspheres
08:29

Microvascular Embolism Mouse Model for In Vivo Two-photon Microscopy Using Fluorescent Polystyrene Microspheres

Published on: November 21, 2025

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

Related Experiment Videos

Last Updated: May 19, 2026

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
11:08

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

Microvascular Embolism Mouse Model for In Vivo Two-photon Microscopy Using Fluorescent Polystyrene Microspheres
08:29

Microvascular Embolism Mouse Model for In Vivo Two-photon Microscopy Using Fluorescent Polystyrene Microspheres

Published on: November 21, 2025

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

Area of Science:

  • Hematology
  • Pathology
  • Internal Medicine

Background:

  • Thrombotic microangiopathy (TMA) is characterized by microvascular thrombosis, leading to microangiopathic hemolytic anemia, thrombocytopenia, and elevated lactate dehydrogenase.
  • The clinical and laboratory findings of TMA are not indicative of a single disease but represent a spectrum of underlying pathologies.

Purpose of the Study:

  • To review the major causes of thrombotic microangiopathy.
  • To provide an overview of the diverse etiologies contributing to TMA.

Main Methods:

  • Literature review of thrombotic microangiopathy.
  • Synthesis of information on various TMA causes.

Main Results:

  • Thrombotic microangiopathy encompasses conditions such as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), bacterial infections, medication-induced toxicity, and vascular or endothelial pathologies.
  • Congenital and acquired forms of TTP/HUS are significant contributors to TMA.
  • Kasabach-Merritt phenomenon and complications arising from stem cell transplantation are also recognized causes of TMA.

Conclusions:

  • Thrombotic microangiopathy is a syndrome with multiple potential underlying causes.
  • Understanding the diverse etiologies is crucial for accurate diagnosis and management of TMA.
  • This review highlights key conditions associated with TMA, emphasizing the need for comprehensive etiological investigation.